ProCE Banner Activity

My Thoughts on the Expanding Roles of Bevacizumab and PARP Inhibitors in Ovarian Cancer Treatment

Clinical Thought
In this commentary, I share my thoughts on recent clinical data and how clinicians can make the best use of both bevacizumab and PARP inhibitors in treating their patients with advanced ovarian cancer.

Released: September 11, 2017

Expiration: September 10, 2018

No longer available for credit.

Share

Faculty

Ursula Matulonis

Ursula Matulonis, MD

Chief, Division of Gynecologic Oncology
Brock-Wilson Faculty Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AstraZeneca

Genentech Roche Virology

Faculty Disclosure

Primary Author

Ursula Matulonis, MD

Chief, Division of Gynecologic Oncology
Brock-Wilson Faculty Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Ursula Matulonis, MD, has disclosed that she has received consulting fees from 2X Oncology, Clovis Pharmaceuticals, and Lilly.